E 2496 NCIC SWOG CALGB ABVD vs Stanford
E 2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) Stratification 0 -2 vs 3 -7 adverse factors* Locally extensive vs Stage III/IV Untreated Stage III/IV, or Locally Extensive (>1/3 mediastinum) HL ABVD x 6 -8 + IFRT (36 Gy) to bulky mediastinal lesions n=428 R n=854 Stanford V + IFRT (36 Gy) to lesions >5 cm n=426 Outcomes Failure-Free Survival (FFS)** Overall Survival (OS) FFS: Time from randomization to progression, relapse or death, whichever occurred first ABVD Dosage Stanford V Dosage Doxorrubicin 25 mg/m 2 IV días 1 y 15 Doxorrubicin 25 mg/m 2 IV weeks 1, 3, 5, 7, 9 and 11 Bleomycin 10 u/m 2 IV días 1 y 15 Vinblastine 6 mg/m 2 IV weeks 1, 3, 5, 7, 9 and 11 Vinblastine 6 mg/m 2 IV días 1 y 15 Nitrogen mustard 6 mg/m 2 IV weeks 1, 5, and 9 Dacarbazine 375 mg/m 2 IV días 1 y 15 Etoposide 60 mg/m 2 x 2 V weeks 3, 7, and 11 Vincristine 1. 4 mg/m 2 IV weeks 2, 4, 6, 8, 10 and 12 Bleomycin 5 u/m 2 IV weeks 2, 4, 6, 8, 10 and 12 Prednisone 40 mg q other day x 12 weeks (Taper week 10 -12) Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: 10. 1200/JCO. 2012. 43. 4803 Creada por: Mauricio Lema Medina MD 1/2
E 2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) % ABVD remains the standard of care for patients with advanced Hodgkin lymphoma. Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: 10. 1200/JCO. 2012. 43. 4803 Creada por: Mauricio Lema Medina MD 2/2
Treatment of Advanced Hodgkin Lymphoma: The More Things Change, the More They Stay the Same Longo DL. J Clin Oncol DOI: 10. 1200/JCO. 2012. 44. 7235
- Slides: 3